Oragenics
OGEN
10 hedge funds and large institutions have $350K invested in Oragenics in 2023 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 0 closing their positions.
58% more capital inflows, than outflows
Capital inflows: $7.46K | Capital outflows: $4.73K
0% more funds holding
Funds holding: 10 → 10 (0)
0% less ownership
Funds ownership: 2.42% → 2.42% (-0%)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$7.46K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Tower Research Capital (TRC)
New York
|
-$4.38K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$355 |
OGEN Hedge Fund Activity: Q4 2023 in Review
10 of the 6,876 institutional investors tracked by Wall St. Rank reported a position in Oragenics (OGEN) for Q4 2023, worth a combined $350K — up 92% from $182K a quarter earlier.
Fund positioning in OGEN was balanced in Q4 2023: 0 funds opened new positions, 0 closed out, 1 added to existing stakes and 2 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $7.46K. The largest seller was Tower Research Capital (TRC), cutting an estimated $4.38K.
- 10 institutional investors held Oragenics (OGEN) as of Q4 2023, unchanged from Q3 2023.
- Funds reported $350K of Oragenics stock for Q4 2023, up 92% quarter-over-quarter.
- 0 funds opened new Oragenics positions in Q4 2023 and 0 closed out.
- The largest Oragenics buyer in Q4 2023 was Renaissance Technologies, an estimated $7.46K added.
- The largest Oragenics seller in Q4 2023 was Tower Research Capital (TRC), an estimated $4.38K sold.
Based on aggregated 13F filings for Q4 2023.